Navigation Links
Takeda and Zinfandel Pharmaceuticals Sign Licensing Agreement for Alzheimer's Disease Biomarker in Combination with Pioglitazone
Date:1/10/2011

OSAKA, Japan and DURHAM, N.C., Jan. 10, 2011 /PRNewswire/ -- Takeda Pharmaceutical Company Limited and Zinfandel Pharmaceuticals, Inc. today announced that they have entered into an exclusive, worldwide licensing agreement regarding Zinfandel's TOMM40 assay as a biomarker for the risk of Alzheimer's disease in high-risk older adults with normal cognition. The companies will study pioglitazone in connection with the TOMM40 biomarker and Alzheimer's disease. Pioglitazone is the active ingredient currently marketed in Takeda's ACTOS® (pioglitazone HCl).

The TOMM40 biomarker, recently discovered by a team led by Allen Roses, M.D., Chief Executive Officer of Zinfandel, is being developed to identify individuals at high risk of developing Alzheimer's disease within the subsequent five years. Under this license agreement, Takeda and Zinfandel will attempt to prospectively validate the TOMM40 biomarker as a test of individual risk.

"There is intense interest within the medical community in identifying treatments to help delay progression or potentially prevent the onset of Alzheimer's disease, in an effort to reduce the burden of this disease," said Shigenori Ohkawa, Ph.D., Chief Scientific Officer, Takeda Pharmaceutical Company Limited. "We are energized by this partnership and the opportunity to develop an effective treatment for healthy at-risk older adults."

Under the terms of agreement, Zinfandel will receive an upfront payment of $9 million and subsequent payments of up to $78 million for development milestones from Takeda. Additional commercial milestones and royalties were also outlined in the agreement. Takeda will obtain an exclusive license, with the right to sublicense, develop, make, use and commercialize the TOMM40 biomarker assay, and to use the assay to identify high-risk older adults who would be candidates for clinical trials with pioglitazone to evaluate its utility.

"At Zinfandel, we have been exploring pharmacogene
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited; Zinfandel Pharmaceutcals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Takeda San Francisco, Inc. Appoints Gregory Landes, Ph.D. Vice President of Antibody Research
2. FDA Continues Review of Takedas New Drug Application for Alogliptin (SYR-322), a DPP-4 Agent for Type 2 Diabetes
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
4. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
5. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
6. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
7. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
8. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
9. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
10. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
11. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... -- AACC welcomed thousands of medical professionals and ... & Clinical Lab Expo in Atlanta ... revolutionary advancements in clinical testing technology and research ... diagnose patients quickly and accurately and make sure ... As of Wednesday, July 29, more than 17,500 ...
(Date:7/30/2015)... Washington , July 30, 2015 ... Market, by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial ... Discovery & Development, Preclinical, Clinical Trial), by End Users ... Biosimulation Market is expected to reach USD 2,107.99 million ... a CAGR of 15.29%. Browse more ...
(Date:7/30/2015)... 30, 2015  With over 60,000 customers across the globe, ISN improves the efficiency ... organizations with more than 60,000 safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide ... Headquartered in Dallas, TX , ISN ...
(Date:7/30/2015)... ... ... its 2015 growth plan and as a follow up to the recently announced expansion of ... pleased to announce that it has begun construction on a new Microbiological Laboratory. The new ... dedicated to basic USP 51, USP 61, and USP 62 testing specific to raw materials. ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2
... Nov. 10 Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) ... months ended Sept. 30, 2008., Third Quarter and ... quarter and nine months ended Sept. 30, 2008, was,$3.8 ... and,$14.5 million respectively in 2007. Revenue in the third ...
... - Completes Restructuring and Two Divestitures of Non-Core ... Caliper Life,Sciences, Inc. (Nasdaq: CALP ) ... the completion of two product line divestitures: the,sale ... for $5.0,million and the sale of its Pharmaceutical ...
... to be Webcast -, MONTVALE, N.J. ,Nov. 10 ... that Noah Berkowitz, M.D.,Ph.D., President and Chief Executive Officer ... Forum on Tuesday, November 11, at 2:25,p.m. Eastern Time. ... at the New,York Palace Hotel in New York City., ...
Cached Biology Technology:Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 2Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 3Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 4Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 5Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 6Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 2Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 3Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 4Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 5Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 6Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 7Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 8Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 9Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 10Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 11Synvista Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference 2
(Date:7/13/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ... today announced sampling of ClearPad ® 4300, ... (TDDI) product targeting smartphones and tablets. This new ... , best-in-class touch controller IP and systems ... in the company,s Japan Design Center. TDDI enables ...
(Date:7/9/2015)... Calif. , July 9, 2015  Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... Thursday, July 30, 2015 after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
(Date:7/9/2015)... 2015  Unchained Labs just can,t get enough ... Avid Nano. Avid Nano designs, develops and manufactures ... Also today, Unchained Labs UNcaged the ... use protein sizing system. The pUNk is a ... size, size distribution, aggregation population and molecular weight. ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
... and money while reducing print quality. University of Missouri engineers ... eye. "The nozzle cover we invented was inspired ... in the College of Engineering. "The eye and an ink ... allowed to dry while, simultaneously, they must open. We used ...
... in German . Global warming also ... from the University of Zurich demonstrate that there is insufficient ... Burgundy blood algae are increasingly thriving. The warmer temperatures are ... Many large lakes in Central Europe became ...
... Committee (PBC; a sub-committee of the Council for Higher ... of Sciences committee and announced that a consortium headed ... to establish Israel,s national Center for Mediterranean Sea Research. ... which are universities): The University of Haifa; the Technion; ...
Cached Biology News:Human eye inspires clog-free ink jet printer invented by MU researcher 2Global warming harms lakes 2Global warming harms lakes 3Israel to set up National Center for Mediterranean Sea Research, headed by U of Haifa 2